证券代码：002424 证券简称：ST 百灵 公告编号：2024-039 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）股票（证券简称：ST 百灵，证券代码：002424）连续 3 个交 易日（2024 年 5 月 8 日、2024 年 5 月 9 日、2024 年 5 月 10 日）日 收盘价格跌幅偏离值累计超过12%，根据深圳证券交易所的有关规定， 属于股票交易异常波动的情况。 二、公司关注及核实情况说明 1、公司未发现前期披露的信息存在需要更正、补充之处； 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所 股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有 关的筹划、商谈、意向、协议等；董事会也未获悉本公司有根据《深 圳证券交易所股票上市规则》等有关规定应予以披露而未披露的、对 本公司股票及其衍生品种交易价格产生较大影响的信息；公司前期披 露的信息不 ...

一、股票交易异常波动的情况 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）股票（证券简称：ST 百灵，证券代码：002424）连续 2 个交 易日（2024 年 5 月 6 日、2024 年 5 月 7 日）日收盘价格涨跌幅偏离 值累计达到-12%，根据深圳证券交易所的有关规定，属于股票交易异 常波动的情况。 证券代码：002424 证券简称：ST 百灵 公告编号：2024-037 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 二、公司关注及核实情况说明 1、公司未发现前期披露的信息存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格 产生较大影响的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项，股票异常 波动期间，公司控股股东、实际控制人未买卖公司股票； 5、公司不存在导致股票交易严重异常波动的未披露事项。 三、是否存 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-038 贵州百灵企业集团制药股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日召开第六届董事会第六次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价的方式回购 公司部分股份，用于后期实施股权激励或员工持股计划。回购的资金 总额不低于人民币10,000 万元（含），不超过人民币20,000万元（含）， 回购股份数量区间预计为 844.00 万股（含）至 1,688.00 万股（含）， 回购价格不超过人民币 11.85 元/股（含），回购股份的实施期限为自 董事会审议通过回购股份方案之日起不超过 6 个月。具体内容详见公 司 2024 年 2 月 3 日在《证券时报》《证券日报》《中国证券报》和 巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的 公告暨回购报告书》（公告编号：2024-002）。 根据《上市公司股份回 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-035 特别提示： 公司控股股东姜伟先生质押股份数量为 204,834,668 股，累计占 其所持公司股份数量比例 83.49%，请投资者注意相关风险。 近日，贵州百灵企业集团制药股份有限公司（以下简称"本公司"） 接到控股股东姜伟先生函告，获悉姜伟先生近日将已质押给海通证券股 份有限公司的部分股票办理股票质押式回购交易延期购回，具体事项如 下： 股东 名称 是否为 控股股 东或第 一大股 东及其 一致行 动人 本次质押数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 为补 充质 押 质押起始 日 质押到期 日 延期购 回后到 期日 质权 人 质押用 途 姜伟 是 12,875,998 5.25% 0.91% 否 否 2017 年 8 月 22 日 姜伟 是 2,000,000 0.82% 0.14% 否 是 2018 年 2 月 8 日 一、本次股份质押延期购回的基本情况 | 姜伟 | 是 | 5,000,000 | 2.04% | 0.35% | 否 | 是 | 2018 年 6 | | | | | | -- ...

贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集 团制药股份有限公司(以下简称"公司")委托,指派本所律师郑锡 国、文廷杰出席了公司于 2024年 5月 6 日上午 10:00 在贵州省安顺 市经济技术开发区西航路 212 号贵州百灵企业集团制药股份有限公 司会议室召开的公司 2024 年第二次临时股东大会(以下简称"本次 股东大会")。现根据《中华人民共和国公司法》、《中华人民共和 国证券法》及《上市公司股东大会规则》等有关法律、法规及规章和 《贵州百灵企业集团制药股份有限公司章程》（以下简称〈"公司章 程"）、《贵州百灵企业集团制药股份有限公司股东大会议事规则》 (以下简称"议事规则")的规定,出具本法律意见书。 贵州北斗星律师事务所 BEIDOUXING LAW OFFICE 贵州省贵阳市观山湖区金朱东路 399号贵阳恒大中心 B 座 24 楼 邮编:550001 电话:86901517 传真:869016 电子邮箱:1026333654(a 关于贵州百灵企业集团制药股份有限公司 2024 年第二次临时股东大会 法律意见书 [2024] 黔北律法意见字第 92 号 致:贵州百灵企业集团制药股份 ...

证券代码：002424 证券简称： ST百灵 公告编号：2024-036 贵州百灵企业集团制药股份有限公司 关于注销回购股份减少注册资本暨通知债权人的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、通知债权人原因 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于 2024 年 5 月 6 日召开 2024 年第二次临时股东大会，审议通过了《关于变 更回购股份用途并注销的议案》《关于修订<公司章程>的议案》，公司 拟对已回购的部分股份的用途进行变更，回购股份用途由"用于员工 持股计划或者股权激励"变更为"用于注销并相应减少注册资本"， 即拟对回购专用证券账户中部分股份 13,601,600 股进行注销并相应 减少注册资本， 本 次注 销 完 成后 ， 公 司注 册 资 本将 由 人 民 币 1,411,200,000 元变更为人民币 1,397,598,400 元。具体内容详见 公司在巨潮资讯网披露的《关于变更回购股份用途并注销的公告》（公 告编号：2024-018）。 二、债权申报工作安排 本公司债权人自本通知公告之日起 45 日内，均有权凭 ...

证券代码：002424 证券简称： ST百灵 公告编号：2024-034 贵州百灵企业集团制药股份有限公司 关于参加 2024 年贵州辖区上市公司投资者集体接待 日暨 2023 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 召开方式：网络远程方式 出席本次活动人员：公司总经理、董事、董事会秘书牛民先生； 财务总监李红星先生；独立董事胡坚先生。 参与方式：投资者可登录 http://rs.p5w.net 进入专区页面参 与交流。 二、投资者问题提前征集 为广泛听取投资者的意见和建议、提升交流效率和针对性，本次 业绩说明会公司将提前向广大投资者开展问题征集，提问通道自本公 告发出之日起开放至 2024 年 5 月 7 日截止。请投资者通过微信关 注"贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在本次说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次业绩说明会。 特此公告。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）2023 年年度报告全文及摘要已于 2024 年 4 月 30 日刊登于中国证 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-033 贵州百灵企业集团制药股份有限公司 关于 2024 年第二次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2024年5月6日（星期一）上午十时 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2024 年 5 月 6 日（现场股东大会召开当日）的交易时间， 即 9:15—9:25,9:30—11:30 和 13:00—15:00。通过深圳证券交易所 互联网投票系统进行网络投票的开始时间为 2024 年 5 月 6 日（现场 股东大会召开当日）9:15，结束时间为 2024 年 5 月 6 日（现场股东 大会结束当日）15:00。 2、召开地点：贵州省安顺市经济技术开发区西航路 212 号贵州 百灵企业集团制药股份有限公司会议室 3、召开方式：现场投票和网络投票相结 ...

Financial Performance - The company's revenue for Q1 2024 was ¥1,332,744,270.05, representing a 22.09% increase compared to ¥1,091,626,153.16 in the same period last year[11] - Net profit attributable to shareholders decreased by 44.00% to ¥51,695,103.14 from ¥92,306,394.78 year-on-year[11] - Basic and diluted earnings per share fell by 42.86% to ¥0.04 from ¥0.07 in the same quarter last year[11] - The net profit for the first quarter of 2024 was CNY 51,074,838.51, a decrease of 44.5% compared to CNY 91,853,787.63 in the same period last year[30] - The total profit for the first quarter was CNY 64,666,186.76, down from CNY 125,645,269.48, reflecting a decline of 48.5% year-over-year[30] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥-254,664,208.38, a decline of 340.05% compared to ¥-57,871,366.46 in the previous year[11] - Cash and cash equivalents at the end of the period totaled ¥286,905,027.85, down from ¥471,054,001.52 at the end of the previous period[46] - The company’s cash and cash equivalents were reported at CNY 1,200,000,000.00, indicating a stable liquidity position[27] - Cash inflow from financing activities was ¥541,065,828.18, compared to ¥476,702,269.62 in the prior period, indicating a 13.5% increase[46] - Cash flow from financing activities generated a net amount of CNY 152,285,614.18, showing an increase in financing scale compared to the previous year[36] Assets and Liabilities - Total assets increased by 6.05% to ¥7,793,968,923.01 from ¥7,349,081,335.53 at the end of the previous year[11] - The total liabilities increased to ¥4,300,273,919.08 from ¥3,821,833,000.42, reflecting a growth of 12.5%[45] - Current liabilities increased to CNY 4,045,112,372.70, compared to CNY 3,516,562,997.56, marking a growth of approximately 15.03%[26] - Short-term borrowings rose to CNY 1,598,493,527.89 from CNY 1,436,017,612.52, representing an increase of about 11.29%[26] - Long-term borrowings decreased to CNY 149,713,888.90 from CNY 199,776,527.78, showing a decline of about 25.06%[26] Equity and Shareholder Information - The company's equity attributable to shareholders decreased by 0.94% to ¥3,479,423,576.57 from ¥3,512,356,643.12 at the end of the previous year[11] - The company reported a total equity of CNY 3,748,856,550.31, reflecting an increase from the previous period[27] - The number of ordinary shareholders at the end of the reporting period was 106,426, with the largest shareholder holding 17.39% of the shares[36] Research and Development - Research and development expenses decreased by 81.54% to ¥3,020,082.42 compared to ¥16,358,969.36 in the same period last year[19] - Ongoing R&D investments in new technologies are expected to reach CNY 200 million in 2024, focusing on innovative pharmaceutical solutions[27] - The company incurred research and development expenses of ¥3,020,082.42, significantly lower than ¥16,358,969.36 in the previous period[45] Market Strategy and Future Outlook - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[27] - The company aims to expand its market presence and enhance product development in the upcoming quarters, focusing on innovation and strategic partnerships[37] - The company’s revenue for the first quarter of 2024 is projected to grow by 10% year-over-year, driven by new product launches[27] Accounts Receivable and Inventory - Accounts receivable increased by 38.05% to ¥2,389,302,456.37, primarily due to an increase in sales on credit[19] - Accounts receivable increased to CNY 2,389,302,456.37 from CNY 1,730,811,639.87, representing a rise of 38.0% year-over-year[39] - Inventory at the end of the first quarter was CNY 1,218,788,365.67, compared to CNY 1,163,683,187.16 at the beginning of the year, reflecting a growth of 4.7%[39] Investment Income - The company reported a significant decrease in investment income, down 34.18% to ¥-5,833,183.59 from ¥-4,347,137.40 year-on-year[19] - The company's interest income and other income totaled CNY 4,627,661.00, while investment losses amounted to CNY -5,833,183.59, indicating a challenging investment environment[30] - The company received government subsidies amounting to ¥2,279,424.81 during the reporting period[15]

Financial Performance - The company's operating revenue for 2023 was CNY 4,262,971,440.21, representing a 20.42% increase compared to CNY 3,540,132,272.77 in 2022[36]. - The net profit attributable to shareholders for 2023 was a loss of CNY 414,511,221.17, a decrease of 399.34% from a profit of CNY 138,197,456.35 in 2022[36]. - The net cash flow from operating activities decreased by 74.95% to CNY 125,767,058.47 in 2023, down from CNY 502,152,213.26 in 2022[36]. - The basic earnings per share for 2023 was -0.3 CNY, a decline of 400.00% compared to 0.1 CNY in 2022[36]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of CNY 441,446,776.09 in 2023 compared to a profit of CNY 83,509,504.43 in 2022, marking a decrease of 626.87%[36]. - The weighted average return on net assets for 2023 was -11.17%, down from 3.52% in 2022, indicating a significant decline in profitability[36]. - The company reported a significant increase in deferred income to RMB 24,938,504.65 from RMB 12,358,206.28, suggesting improved revenue recognition practices[152]. - The company reported a net loss of approximately $412.46 million, a significant decline from a net profit of $136.25 million in the previous period[177]. - The company reported a net loss of CNY 552,036,960.69, compared to a net profit of CNY 8,646,515.68 in the previous period, indicating a significant decline in profitability[181]. Assets and Liabilities - Total assets at the end of 2023 were CNY 7,349,081,335.53, an increase of 6.59% from CNY 6,894,398,806.75 at the end of 2022[36]. - As of December 31, 2023, the total liabilities of Guizhou Bai Ling Company amounted to RMB 3,413,246,737.83, an increase from RMB 2,528,024,085.21[152]. - The total equity decreased to RMB 3,062,903,339.04 from RMB 3,681,863,152.17, indicating a decline in shareholder value[152]. - The total assets of Guizhou Bai Ling Company reached RMB 6,476,150,076.87, up from RMB 6,209,887,237.38, showing growth in asset base[152]. - Non-current liabilities rose to approximately $3.82 billion, compared to $2.90 billion, marking an increase of around 31.93%[172]. - The company's total equity decreased to approximately $3.53 billion from $3.99 billion, a decline of about 11.66%[172]. Regulatory and Compliance Issues - The company has received a negative opinion on its internal control audit report for 2023 due to issues with the authenticity and completeness of disclosed sales expenses[18]. - The company received an administrative regulatory decision from the Guizhou Securities Regulatory Bureau on December 22, 2023, due to inaccurate information disclosure in the annual reports for 2021 and 2022[63]. - The regulatory issues were attributed to unrecorded sales expenses, misreported physical gifts, incorrect tax liabilities, and improper goodwill impairment testing[63]. - The company is required to correct these issues and has received warning letters for the responsible executives[63]. - The audit report contained reserved opinions, indicating that further verification is needed by the auditing firm[43]. Shareholder and Investment Activities - The company plans not to distribute cash dividends or issue bonus shares for the year[19]. - The company plans to repurchase shares amounting to 1 billion RMB to 2 billion RMB, representing 0.51% to 1.02% of the total share capital[90]. - The company has a total of CNY 0 million in guarantees provided to shareholders, actual controllers, and their related parties[73]. - The company faces disputes regarding shareholding ratios with minority shareholders of its subsidiary, He Ren Tang Pharmaceutical[135]. Operational Strategies and Future Outlook - The company has implemented strategic procurement and reserve management to control raw material costs amid rising expenses[92]. - The company aims to enhance production efficiency through automation and intelligent scheduling to reduce production costs[92]. - The company anticipates growth in its leading product, Yindan, over the next two years[93]. - Guizhou Bailing aims to strengthen its leading position in the苗药 (Miao medicine) sector and enhance its competitive advantage in the traditional Chinese medicine market[109]. - The company plans to focus on internal control improvements and aims to achieve profitability through enhanced operational efficiency[110]. - Guizhou Bailing intends to explore new economic growth points while continuing to develop its core business areas[113]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[178]. Cash Flow and Financing Activities - The cash and cash equivalents decreased to RMB 417,938,537.62 from RMB 605,022,761.98, reflecting a cash flow challenge[170]. - The net cash flow from financing activities was CNY -233,800,657.67, an improvement from the previous net outflow of CNY -308,382,378.07[187]. - The company’s total cash outflow from financing activities was CNY 1,848,900,657.67, compared to CNY 1,786,982,378.07 in the previous period[187]. Inventory and Accounts Receivable - Accounts receivable stood at RMB 1,730,811,639.87, with a provision for bad debts of RMB 364,880,700, resulting in a net value of RMB 1,365,930,939.87[156]. - Inventory, excluding certain raw materials, was valued at RMB 1,163,683,187.16, with a provision for inventory impairment of RMB 15,336,900, leading to a net value of RMB 1,148,346,287.16[159]. - The company reported a significant discrepancy between actual sales and projected sales for a specific苗药 product, raising concerns about inventory valuation[119]. Research and Development - Research and development expenses increased to approximately $42.04 million, up from $22.40 million, reflecting a growth of about 87.61%[177].